SAR425899, a once-weekly GLP-1 and glucagon receptor dual agonist, achieved placebo-adjusted mean HbA1c level reductions up to 0.75% in patients with overweight or obesity and T2D11. This evidence concerns the gene GCGR and obesity due to melanocortin 4 receptor deficiency.